PBMC expression of PPARγ and NF-κB mRNA and its correlation with cardiovascular remodeling in patients with hypertensive renal injury

doi:10.3877/cma.j.issn.2095-3216.2022.05.005

Abstract

Abstract:

Objective

To explore the peripheral blood mononuclear cells (PBMC) expression of PPARγ and NF-κB mRNA and its correlation with cardiovascular remodeling in patients with hypertensive renal injury.

Methods

From May 2016 to May 2019 in our hospital, 65 patients with hypertension were selected as the simple hypertension group, and 50 patients with hypertensive renal injury were selected as the hypertensive renal injury group, while 50 healthy persons were selected as the control group. The expression of PPARγ mRNA and NF-κB mRNA in PBMC was measured. Cardiac and vascular ultrasound was used to detect the remodeling indicators of carotid artery and heart: carotid artery mean intima-media thickness (IMT), carotid plaque score, and left ventricular mass index (LVMI). Pearson analysis was used to analyze the correlation between the expression of PPARγ and NF-κB mRNA and cardiovascular remodeling indexes. Multiple linear regression method was used to analyze the influencing factors of IMT in the patients with hypertensive renal injury.

Results

Compared with those in the control group, the IMT, plaque score, LVMI, and NF-κB mRNA expression were significantly higher in the simple hypertension group and hypertensive renal injury group, while the PPARγ mRNA expression was significantly lower (P<0.05). The IMT, plaque score, LVMI, and NF-κB mRNA expression in the hypertensive renal injury group were significantly higher than those in the simple hypertension group, while the PPARγ mRNA expression was significantly lower than that in the simple hypertension group (P<0.05). In the hypertensive renal injury group, the expression of PPARγ mRNA was negatively correlated with IMT, plaque score, and LVMI (P<0.05), but the expression of NF-κB mRNA was positively correlated with IMT, plaque score, and LVMI (P<0.05). The decrease of PPARγ mRNA and the increase of NF-κB mRNA were the influencing factors of IMT in patients with hypertensive renal injury (P<0.05).

Conclusion

The expression of PPARγ mRNA in PBMC of patients with with hypertensive renal injury was significantly decreased, while the expression of NF-κB mRNA was significantly increased. Both of them were correlated with the cardiovascular remodeling.

Key words: Hypertensive renal injury, Peroxisome proliferator activated receptor γ, Nuclear factor-κB, Cardiovascular remodeling, Correlation

Guangtao Chen, Liqiang Wu, Xiong Zhuang. PBMC expression of PPARγ and NF-κB mRNA and its correlation with cardiovascular remodeling in patients with hypertensive renal injury[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2022, 11(05): 270-275.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2022.05.005

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2022/V11/I05/270

Figures/Tables 6

References 16

[1]	Carriazo S, Vanessa Perez-Gomez M, Ortiz A. Hypertensive nephropathy: a major roadblock hindering the advance of precision nephrology [J]. Clin Kidney J, 2020, 13(4): 504-509.
[2]	Rubenstein DA, Yin W. Platelet-activation mechanisms and vascular remodeling [J]. Compr Physiol, 2018, 8(3): 1117-1156.
[3]	Jain RB. Trends in the levels of urine and serum creatinine: data from NHANES 2001-2014 [J]. Environ Sci Pollut Res Int, 2017, 24(11): 10197-10204.
[4]	刘娟，李晓燕，孙青，等. 冠心病合并糖代谢异常患者血浆PPAR-γ、APN及胰岛素抵抗水平的变化[J]. 中国心血管病研究杂志，2014, 12(8): 702-706.
[5]	Shu J, Liu W, Han F, et al. Trimethoxystilbene reduces nuclear factor kappa b, interleukin-6, and tumor necrosis factor-α levels in rats with pulmonary artery hypertension [J]. Biomed Res Int, 2019, 2019: 1219848.
[6]	Korbecki J, Bobiński R, Dutka M. Self-regulation of the inflammatory response by peroxisome proliferator-activated receptors [J]. Inflamm Res, 2019, 68(6): 443-458.
[7]	中国高血压防治指南修订委员会. 中国高血压防治指南2010[J]. 中华心血管病杂志，2011, 39(7): 579-616.
[8]	王海燕. 肾脏病临床概览[M]. 北京：北京大学医学出版社，2010: 339-340.
[9]	姚佳梅，陈雨丝，杨斌，等. 原发性高血压病肝阳上亢证与临床指标的相关性分析[J]. 中华中医药学刊，2019, 37(10): 2318-2323.
[10]	Inaguma D, Ito E, Takahashi K, et al. Impact of high mortality in incident dialysis patients due to hypertensive nephrosclerosis: a multicenter prospective cohort study in Aichi, Japan [J]. Clin Exp Nephrol, 2018, 22(6): 1360-1370.
[11]	Liu T, Liu M, Shang P, et al. Investigation into the underlying molecular mechanisms of hypertensive nephrosclerosis using bioinformatics analyses [J]. Mol Med Rep, 2018, 17(3): 4440-4448.
[12]	于敏，于爱清，于杜娟，等. 瑞舒伐他汀联合缬沙坦干预对高血压并发阵发性心房颤动患者血浆超敏C反应蛋白和心肌重构的影响[J]. 中国实验诊断学，2017, 21(7): 1141-1144.
[13]	De Silva TM, Li Y, Kinzenbaw DA, et al. Endothelial PPARγ (peroxisome proliferator-activated receptor-γ) is essential for preventing endothelial dysfunction with aging [J]. Hypertension, 2018, 72(1): 227-234.
[14]	Luo XY, Zhu XQ, Li Y, et al. MicroRNA-150 restores endothelial cell function and attenuates vascular remodeling by targeting PTX3 through the NF-κB signaling pathway in mice with acute coronary syndrome [J]. Cell Biol Int, 2018, 42(9): 1170-1181.
[15]	姜芊竹，张琪，杨建飞，等. 基于IKK/IκB/NF-κB信号通路探讨养心颗粒干预急性心肌梗死后心室重构的作用机制[J]. 中西医结合心脑血管病杂志，2022, 20(3): 427-431.
[16]	夏勇，王震，刘杨，等. 高血压患者外周血IGF-1、TGF-β1水平与心血管重构和肾损伤的关系[J]. 中国循证心血管医学杂志，2018, 10(6): 668-671.

基因	正向引物5′-3′	反向引物5′-3′
PPARγ mRNA	GTCTCACAATGCCATCAGGTT	TTCAGCTGGTCGATATCACT
内参β-actin	GCATGGGTCAGAAGGATTCCT	TCGTCCCAGTTGGTGACGAT
NF-κB mRNA	TCTCGCCTGCCTCCACAAG	TGTCTCCACGCCGCTGTC
内参GAPDH	GGTTCGCATGGCCTTCAG	AGGAGTGGGTGTCGCTGT

基因	正向引物5′-3′	反向引物5′-3′
PPARγ mRNA	GTCTCACAATGCCATCAGGTT	TTCAGCTGGTCGATATCACT
内参β-actin	GCATGGGTCAGAAGGATTCCT	TCGTCCCAGTTGGTGACGAT
NF-κB mRNA	TCTCGCCTGCCTCCACAAG	TGTCTCCACGCCGCTGTC
内参GAPDH	GGTTCGCATGGCCTTCAG	AGGAGTGGGTGTCGCTGT

临床资料	对照组(n＝50)	单纯高血压组(n＝65)	高血压肾损伤组(n＝50)	χ²/F值	P值
性别(男/女)	25/25	35/30	27/23	0.214	0.898
年龄(岁)	67.84±7.55	67.21±7.16	68.10±7.34	0.227	0.797
体质指数(kg/m²)	22.57±3.09	22.98±3.22	23.11±3.45	0.381	0.684
舒张压(mmHg)	82.14±10.20	95.23±11.43^a	101.12±10.55^ab	40.757	0.000
收缩压(mmHg)	127.68±13.46	148.46±14.52^a	153.24±16.78^ab	42.511	0.000
总胆固醇(mmol/L)	4.76±0.96	5.02±0.88	5.20±1.02	2.726	0.068
三酰甘油(mmol/L)	1.20±0.37	1.25±0.42	1.38±0.47	2.454	0.089
低密度脂蛋白(mmol/L)	2.02±0.51	2.24±0.67^a	2.53±0.73^ab	7.851	0.001
高密度脂蛋白(mmol/L)	1.30±0.34	1.19±0.28	1.24±0.36	1.627	0.200
血肌酐(μmol/L)	65.58±13.25	75.22±15.13^a	83.45±16.78^ab	17.496	0.000
血尿素氮(mmol/L)	5.87±1.31	6.48±1.44^a	7.62±1.52^ab	19.471	0.000
尿转铁蛋白(mg/L)	1.20±0.35	5.42±0.88^a	7.01±1.29^ab	538.813	0.000
尿微量蛋白(mg/L)	12.45±2.41	66.64±16.54^a	78.25±14.78^ab	358.416	0.000

临床资料	对照组(n＝50)	单纯高血压组(n＝65)	高血压肾损伤组(n＝50)	χ²/F值	P值
性别(男/女)	25/25	35/30	27/23	0.214	0.898
年龄(岁)	67.84±7.55	67.21±7.16	68.10±7.34	0.227	0.797
体质指数(kg/m²)	22.57±3.09	22.98±3.22	23.11±3.45	0.381	0.684
舒张压(mmHg)	82.14±10.20	95.23±11.43^a	101.12±10.55^ab	40.757	0.000
收缩压(mmHg)	127.68±13.46	148.46±14.52^a	153.24±16.78^ab	42.511	0.000
总胆固醇(mmol/L)	4.76±0.96	5.02±0.88	5.20±1.02	2.726	0.068
三酰甘油(mmol/L)	1.20±0.37	1.25±0.42	1.38±0.47	2.454	0.089
低密度脂蛋白(mmol/L)	2.02±0.51	2.24±0.67^a	2.53±0.73^ab	7.851	0.001
高密度脂蛋白(mmol/L)	1.30±0.34	1.19±0.28	1.24±0.36	1.627	0.200
血肌酐(μmol/L)	65.58±13.25	75.22±15.13^a	83.45±16.78^ab	17.496	0.000
血尿素氮(mmol/L)	5.87±1.31	6.48±1.44^a	7.62±1.52^ab	19.471	0.000
尿转铁蛋白(mg/L)	1.20±0.35	5.42±0.88^a	7.01±1.29^ab	538.813	0.000
尿微量蛋白(mg/L)	12.45±2.41	66.64±16.54^a	78.25±14.78^ab	358.416	0.000

组别	例数	IMT(mm)	斑块积分(分)	LVMI(g/m²)
对照组	50	0.83±0.20	2.48±0.77	89.67±10.65
单纯高血压组	65	1.01±0.25^a	4.30±1.13^a	125.25±13.26^a
高血压肾损伤组	50	1.14±0.19^ab	6.67±1.64^ab	133.74±16.44^ab
F值		25.437	147.559	150.339
P值		0.000	0.000	0.000

Please choose a citation manager

Content to export